osimertinib dimesylate

Osimertinib dimesylate is an irreversible and mutant selective EGFR inhibitor (IC50s: 12 and 1 nM against EGFR L858R and EGFR L858R/T790M).

Osimertinib-D6 is a deuterated compound of Osimertinib. Osimertinib (T2490) has a CAS number of 1421373-65-0. Osimertinib (T2490) is a small molecule tyrosine kinase receptor inhibitor and antineoplastic agent that is used in the therapy of selected forms of advanced non-small cell lung cancer (NSCLC).

Osimertinib-13C,D3 (Standard) is a reference standard of Osimertinib-13C,D3 intended for quantitative analysis, quality control, and related biochemical research applications. Osimertinib-13C,d3 is a deuterated form of Osimertinib labeled with 13C. Osimertinib (AZD9291) is an orally active, covalent, irreversible EGFR inhibitor with mutation selectivity, effectively inhibiting L858R (IC50=12 nM) and L858R/T790M (IC50=1 nM) EGFR mutations. It addresses resistance to EGFR inhibitors caused by the T790M mutation in lung cancer.

Osimertinib mesylate (AZD-9291 mesylate) is an EGFR third-generation inhibitor that inhibits the T790M resistance mutation produced by second-generation EGFR inhibitors with irreversible and oral activity. Osimertinib mesylate has antitumor activity for the treatment of EGFR-mutated non-small-cell lung cancer.

Osimertinib-13C,D3 is a deuterated form of Osimertinib (T2490) labeled with 13C. Osimertinib (T2490) (AZD9291) is an orally active, covalent, irreversible EGFR inhibitor with mutation selectivity, effectively inhibiting L858R (IC50=12 nM) and L858R/T790M (IC50=1 nM) EGFR mutations. It addresses resistance to EGFR inhibitors caused by the T790M mutation in lung cancer.

Osimertinib (AZD-9291) is an EGFR third-generation inhibitor that inhibits the T790M resistance mutation produced by second-generation EGFR inhibitors with irreversible and oral activity. Osimertinib has antitumor activity for the treatment of EGFR-mutated non-small-cell lung cancer.

Osimertinib (Standard) is a reference standard for research and analysis in studies involving Osimertinib. Osimertinib (AZD-9291) is an EGFR third-generation inhibitor that inhibits the T790M resistance mutation produced by second-generation EGFR inhibitors with irreversible and oral activity. Osimertinib has antitumor activity for the treatment of EGFR-mutated non-small-cell lung cancer.